SOUTH SAN FRANCISCO, Calif., Jan. 28, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational...
Extended cash runway into late 2027, beyond a potentially registration-enabling azenosertib data readout from DENALI Part 2 Planned workforce reduction...
Over 4,000 GMP Capsules Ready to Support PTSD Treatment in Australia, Israel, and CanadaVancouver, British Columbia--(Newsfile Corp. - January 29,...
AAT announces additional significant updates RADNOR, Pa., Jan. 29, 2025 /PRNewswire/ -- Advanced Aesthetic Technologies, Inc. ("AAT") announced today that...
CRSA Joins Ryght Research Network to Accelerate Access to Novel Cancer Therapies LAGUNA BEACH, Calif., Jan. 28, 2025 /PRNewswire/ -- Ryght...
Collaborating to position the Cincinnati region as a top destination for advanced brain tumor care and innovation CINCINNATI, Jan. 28,...
FREMONT, Calif., Jan. 28, 2025 /PRNewswire/ -- Automating data capture by leveraging electronic health records can significantly improve data quality...
NEW YORK, Jan. 28, 2025 /PRNewswire/ -- Surgical Safety Technologies (SST), the pioneer and leading provider of ambient technology healthcare...
NEW YORK and PARIS, Jan. 28, 2025 /PRNewswire/ -- Inato, the leading platform for clinical trial access and inclusivity, today...
Special issue "Advances in Metabolomics for Precision Medicine: From Biomarker Discovery to Clinical Applications" focuses on the latest challenges and...
Advances radiopharmaceutical leadership with addition of scalable manufacturing infrastructure and end-to-end clinical development capabilities Adds OCTEVY™, a registrational-stage diagnostic asset,...
CARY, N.C., Jan. 28, 2025 /PRNewswire/ -- InstantGMP™, a leader in fully integrated GMP-compliant software solutions for pharmaceutical manufacturing, proudly...
Advancement of next-generation APJ agonists with discontinuation of azelaprag Nomination of NLRP3 inhibitor BGE-102 as a development candidate, with initial...
Dual-Targeted CD19/CD70 Allogeneic CAR T: Best-in-Class Design to Enhance Therapeutic Benefit and Expand Treatment Potential Across a Range of Autoimmune...
New preclinical findings provide validation for Silexion’s new systemic administration approach for SIL-204, demonstrating inhibition of tumor growth in a...
Following a constructive Nasdaq hearing panel on January 7, 2025, Evaxion has been granted a 180-day extension in relation to...
Investigational Review Board (IRB) approval has been granted for the open-label study to evaluate tafenoquine for treatment of patients with...
Company prepares to advance to Phase 2 clinical trial in early 2025 HOUSTON, Jan. 28, 2025 (GLOBE NEWSWIRE) -- March...
Appoints Simon Harnest as Chief Financial Officer to advance capital markets and corporate development strategy supporting TOS-358, the Company’s lead...
SAN DIEGO, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing...